This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

In Entresto patent litigation with MSN Pharmaceuticals, Novartis denied leave to amend

( October 21, 2024, 10:10 GMT | Official Statement) -- MLex Summary: A US judge crossed out "granted" and wrote in "denied" on an order proposed by patent owner Novartis, who sought leave to add MSN Pharmaceuticals' US subsidiary Novadoz as a defendant in an infringement action. At issue is MSN's recently-approved abbreviated new drug application for generic combination sacubitril/valsartan tablets. Sacubitril and valsartan are the active ingredients in Novartis's "Entresto" cardiovascular drug.See document below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections